In this episode David Flores, CEO of Spotlight Media Corp, sits down with the founding members of the newly formed Healing REIT that will focus on investing in real estate designed for innovative medicine such as psychedelic-assisted therapy.
Similar Posts
Interview with Rick Doblin, Executive Director and Founder of MAPS
In this episode, Rick and James Hallifax discuss MAPS’ work treating PTSD with MDMA, sending the Soviets Psychedelics, and what the future holds.
Two Psychedelic Companies Run Out of Money: Will it Cause a Domino Effect? | Plus MindMed Stock News
Two Psychedelic Medicines Companies Run out of Money. What is next for psychedelic stocks? Plus a MindMed Stock Update( MMED / MMED)
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC
A second domino is falling in the world of psychedelic stock investing.
Last week, Psychedelic Spotlight reported that Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) was halting its psychedelic medicines research, following a “strategic review” undertaken by the company.
In short, they ran out of money.
As I have stated repeatedly, running a psychedelic research company is ridiculously expensive, and many smaller companies with low market caps and little money in the bank will find it hard to survive in a market context of low stock prices.
At the time, I speculated that “we shouldn’t be surprised if this is just the first domino,” and unfortunately, it didn’t take much time for the prophecy to be realized.
On March 19th, psychedelics company Core One Labs (CSE: COOL) (OTC: CLABF) announced that they are “working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies.”
Or, in other words, they too have run out of money and are looking for a financial savior.
This wasn’t particularly surprising. Taking a cursory look at their financials, we can see the dire position the company is in. As of the end of September, the company had $587,000 CAD in the bank, and they were spending more than $5 million per quarter. With a market cap of around $32 million, Core One would have to dilute their stock by more than 15% each quarter to keep spending at the same levels. This, obviously, is an unsustainable proposition.
So, with two psychedelic medicine companies essentially announcing that they no longer have the financial wherewithal to continue operations, does it mean that the end of psychedelic stocks is near?
No, it most certainly does not.
To start, we need to understand that the psychedelics companies that are beginning to falter are the ones who were already in bad financial shape. There are many companies that have strong financials, and do not need to worry about refinancing any time soon. A short and non-exhaustive list of these companies include: atai Life Sciences (Nasdaq: ATAI); MindMed (Nasdaq: MNMD) (NEO: MMED); and Small Pharma (TSXV: DMT) (OTCQB: DMTTF). Even if — and I judge this to be likely — more small-cap psychedelics companies follow Mind Cure and Core One Labs’ lead, the more financially stable companies won’t be affected.
Sources:
PsychedelicSpotlight.com article: https://psychedelicspotlight.com/another-psychedelics-company-core-one-labs-is-crashing-is-industry-in-trouble/
MindCure Press release: https://www.newswire.ca/news-releases/mindcure-provides-update-on-strategic-review-891232484.html
Core One Labs Press Release: https://www.globenewswire.com/news-release/2022/03/19/2406329/0/en/Core-One-Labs-to-Investigate-Soliciting-Investment-and-Potential-Takeover-Opportunities.html
Core One Labs $100/ gram psilocybin: https://www.globenewswire.com/news-release/2022/02/23/2390219/0/en/Vancouver-discovery-will-make-Magic-Mushroom-mental-health-care-cheaper.html
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#PsychedelicStocks #Psychedelics #Investing
Interview With Daniel Carcillo, Natalie Ginsberg, Olivia Mannix & Klee Irwin
This week on the Psychedelic Spotlight podcast, we provide a recap of the inaugural Benzinga Psychedelic Capital Conference which took place in Fontainebleau Miami Beach on April 19, 2022.
Can Next Generation Psychedelics Treat Mental Illness? | Mindset Pharma | DMT, 5-MEO-DMT
In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).
Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting.
Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.
Excitingly, Mindset is moving towards beginning clinical trials in 2022.
On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs.
In the long term, this deal has great potential for Otsuka.
To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:
Can psychedelics treat mental illnesses such as depression?
Are next-generation psychedelics better than the originals?
What is happening in the brain when a person takes psychedelics?
Enjoy the episode!
You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.
*To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/
#MindsetPharma #DMT #microdosing
MindMed Added To The Russell 3000 and The MSCI Canada Index [Where Does MNMD/MMED Go From Here?]
MindMed (NASDAQ: MNMD), (MMED: NEO) has been added to two major indexes; the Russell 3000 and the Morgan Stanley Capital International Canada Index.
In this segment we will explain what that means and how this news will influence the stock price.
Links:
MindMed (MMED / MNMD) added to the Russell 3000:
https://www.reddit.com/r/MindMedInvestorsClub/comments/nsle8l/mnmd_added_to_the_russell_3000_index/
https://www.reddit.com/r/MindMedInvestorsClub/comments/nsqcz5/big_news_mindmed_has_been_added_to_one_of_the/
MindMed added to the MSCI Canada Index:
https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/neo-exchange-announces-eligibility-in-msci-indexes
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #MindmedNews
MindMed vs. atai Life Sciences (Everything You Need to Know Before Buying MNMD / MMED/ ATAI)
THE MINDMED VS. ATAI discussion you need to hear!
Prior to atai’s IPO on the NASDAQ stock exchange, we repeatedly said that when atai Life Sciences goes public, the company will become MindMed ‘s ( MNMD: NASDAQ) (MMED: NEO) top competitor.
Well, atai did IPO on June 18 under ticker symbol “atai”. For this reason, I invited Jason Najum from Microdose.buzz to have a conversation. In this episode, we have a general discussion about:
– MindMed’s flagship programs and the different businesses and programs ran under atai’s umbrella.
– The companies’ financial capability to run clinical trials.
-MindMed’s and atai’s potential to disrupt the way we treat mental illness within the next 5 to 10 years.
– Potential return on investment for retail investors.
Time Stamps:
0:00 – Intro
4:11 – What is atai’s mission?
6:24 – What is MindMed’s Mission
8:29 – atai’s clinical trial pipeline
19:45 – MindMed’s clinical trial pipeline
24:25 – How do MindMed and atai differ in business structure?
30:40 – Comparing the financials
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Enjoy the episode!
Check out Jason’s writing at:
https://microdose.buzz/
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Website: https://thepsychedelicinvestor.com/
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #Atai